Phase 4Terminated

Efficacy and Safety of NVX-CoV2705 (COVID-19)

A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19

Sponsor
Novavax (Industry)
Enrollment
6,500 enrolled
Conditions
COVID-19; Sars-CoV-2 Infection
Interventions
NVX-CoV2705; Placebo
Ages
adults, older adults
Registry
NCT07086222

Full record on ClinicalTrials.gov

From the registry

This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.

Primary outcomes

  • First episode of PCR-positive symptomatic COVID 19

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered